VRDN

Viridian Therapeutics
VRDN

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$1.10B
EV
$595.28M
Shares Outstanding
81.51M
Beta
0.86

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$39.69
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Viridian Therapeutics, Inc.

gainify
VRDN

Viridian Therapeutics, Inc.

VRDN

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical tr...

Sector

Healthcare

Industry

Biotechnology

CEO

Mahoney, Stephen

Employees

143

IPO Date

2014-06-18

Headquarters

221 Crescent Street, Suite 401, Waltham, Massachusetts, 02453, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved